OnCo
peoplePerson

Se-Hoon Lee

A lung cancer oncologist who has helped test checkpoint inhibitors and next-generation ADCs in Korean patients.

Se-Hoon Lee investigates immunotherapy and antibody-drug conjugates in non-small-cell and small-cell lung cancer, including datopotamab deruxtecan and tarlatamab programmes.

Role
Professor of Internal Medicine; thoracic oncology and immunotherapy
Specialisms
Lung cancerImmunotherapySmall-cell lung cancer

Key papers

1top
rctNew England Journal of Medicine 2024changed practice
MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer

Patients newly diagnosed with EGFR-mutated advanced lung cancer now have a first-line option that improves survival over osimertinib, particularly if they have high-risk features. The trade-off is intravenous (now subcutaneous) infusions and considerably more skin, nail and clotting toxicity, so osimertinib alone remains reasonable for those who prioritise convenience and tolerability. Both this regimen and osimertinib plus chemotherapy (FLAURA2) are approved; there is no direct comparison.

Connected

6top

Pages like this

not linked directly; found by shared links

cancers

2
Non-small-cell lung cancerSmall-cell lung cancer

drugs

2
ApprovedADC
Datopotamab deruxtecan · Datroway
ApprovedBispecific T-cell engager (DLL3×CD3)
Tarlatamab · Imdelltra

institutions

1
Seoul National University Hospital

key papers

1
MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer